BioTech Weekly - Aug 25-31, 2025 (Week 35)

🔬 This Week in BiotechFrom groundbreaking therapeutics to new AI-driven tools, here are the latest developments shaping the future of biotechnology:1️⃣ Promising broad-spectrum antiviral targets discovered in conserved N-glycans 👉 https://www.genengnews.com/topics/infectious-diseases/broad-spectrum-antiviral-strategy-identifies-synthetic-carbohydrate-receptors-that-target-conserved-enveloped-virus-glycans/2️⃣ Raina Biosciences launches advanced generative AI platform for mRNA therapeutics 👉 https://www.genengnews.com/topics/omics/raina-biosciences-unveils-advanced-generative-ai-platform-for-mrna-therapeutics/3️⃣ Akeso reports survival benefits in lung cancer trial 👉 https://www.statnews.com/2025/08/26/akeso-says-its-closely-watched-drug-improved-patient-survival-in-a-lung-cancer-trial/?utm_campaign=rss4️⃣ FDA approval of Stealth’s Barth therapy sparks mixed emotions 👉 https://www.biocentury.com/article/656853/approval-of-stealth-s-barth-therapy-could-be-bittersweet-a-perspective5️⃣ Generative AI opens new doors for mRNA drug design 👉 https://phys.org/news/2025-08-generative-ai-platform-mrna-therapeutics.html6️⃣ Computational tool maps genome changes in 3D 👉 https://phys.org/news/2025-08-tool-genome-dna-3d.html7️⃣ Opinion: The future of medicine lies in multifunctional therapies 👉 https://www.statnews.com/2025/08/25/multifunctional-therapies-drug-development-future-of-medicine/?utm_campaign=rss8️⃣ Massachusetts biotech industry faces tough challenges, new report finds 👉 https://www.statnews.com/2025/08/26/massachusetts-biotech-state-of-industry/?utm_campaign=rssBiotech continues to evolve at an incredible pace — from AI innovations to real-world patient impact.#Biotech #Biotechnology #Science #Innovation #Healthcare #Research #BiotechWeeklyDisclaimer: This podcast includes content generated with the help of large language models (LLM). Although care has been taken to ensure accuracy, LLMs can sometimes produce incorrect or misleading information. Listeners are advised to independently verify any details, provide feedback, and reach out.

There are no comments yet.

Please log in to write the first comment.